Investors



Investor Relations

Stock price graph
             

We are developing a platform of a new class of broad-spectrum catalytic antioxidant compounds based on technology discovered at Duke University and National Jewish Health. Our strategy is to use non-dilutive capital wherever possible to develop our exciting platform of broad-spectrum catalytic antioxidant compounds in important unmet indications of national strategic importance. We plan to continue to leverage that capital, like the investment made by U.S. government agencies, such as NIH-NIAID and NIH CounterACT, in AEOL 10150 as a medical countermeasure, to concurrently develop these promising compounds for use in significant unmet medical indications, like oncology.


Recent Releases

Aug 15, 2016
Aeolus Announces Third Quarter Fiscal Year 2016 Financial Results

May 23, 2016
Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference

View all releases »